CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compound or salt. The present invention also provides a drug for the prevention or treatment of diseases associated with the activation of TLR7, said drug including the aforementioned TLR7 activation inhibitor.

The present disclosure describes terpenophenolic compounds and their use in medicine. The present disclosure further describes perrottetinene-like compounds, the manufacture thereof, formulations containing same and their use in medicine. Such compounds include (1R, 2R)-5-methyl-phenethyl-2-(prop-1-ene-2-yl)-1, 2, 3, 4-tetrahydro-[1, 1-biphenyl]-2,6-diol (CBD-PET) or (1R,2R)-4-(4-hydroxyphenethyl)-5-methyl-2-(prop-1-ene-2-yl)-1, 2, 3, 4-tetrahydro-[1, 1-biphenyl]-2,6-diol (CBD-PET-OH).

The present disclosure describes terpenophenolic compounds and their use in medicine. The present disclosure further describes perrottetinene-like compounds, the manufacture thereof, formulations containing same and their use in medicine. Such compounds include (1R, 2R)-5-methyl-phenethyl-2-(prop-1-ene-2-yl)-1, 2, 3, 4-tetrahydro-[1, 1-biphenyl]-2,6-diol (CBD-PET) or (1R,2R)-4-(4-hydroxyphenethyl)-5-methyl-2-(prop-1-ene-2-yl)-1, 2, 3, 4-tetrahydro-[1, 1-biphenyl]-2,6-diol (CBD-PET-OH).